Lacosamide , 98% , 175481-36-4
CAS NO.：175481-36-4
Empirical Formula: C13H18N2O3
Molecular Weight: 250.29
MDL number: MFCD08272557
EINECS: 605-756-0
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB388.00 | In Stock |
|
| 1g | RMB508.80 | In Stock |
|
| 25MG | RMB1008.00 | In Stock |
|
| 50MG | RMB1094.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 141-143?C |
| alpha | D23 +16.0° (c = 1 in CH3OH) |
| Boiling point: | 536.4±50.0 °C(Predicted) |
| Density | 1.120±0.06 g/cm3(Predicted) |
| Flash point: | 2℃ |
| storage temp. | Refrigerator |
| solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml |
| form | A crystalline solid |
| pka | 14.19±0.46(Predicted) |
| InChI | InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1 |
| InChIKey | VPPJLAIAVCUEMN-GFCCVEGCSA-N |
| SMILES | C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC |
Description and Uses
Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation. It is effective in multiple rodent models of seizure activity. The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway. Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse. Lacosamide is regulated as a Schedule V compound in the United States.
A potent anticonvulsant.
Safety
| Symbol(GHS) |   GHS02,GHS07 |
| Signal word | Danger |
| Hazard statements | H225-H302+H312+H332-H319 |
| Precautionary statements | P210-P280-P305+P351+P338 |
| Hazard Codes | F,Xn |
| Risk Statements | 11-20/21/22-36 |
| Safety Statements | 16-26-36/37 |
| RIDADR | UN 1648 3 / PGII |
| WGK Germany | 2 |
| HS Code | 2924296000 |
